申请人:Richter Gedeon Vegyeszeti Gyar R.T.
公开号:US04048322A1
公开(公告)日:1977-09-13
The invention relates to new xanthene-9-carboxylates of the formula (I), ##STR1## wherein R.sub.1 and R.sub.3 are the same or different and each can represent a lower alkyl group, R.sub.2 is a lower alkyl group or a group of the formula (VI), ##STR2## WHEREIN M IS AN INTEGER OF 2 TO 5, OR R.sub.1 and R.sub.2 form, together with the adjacent nitrogen atom, a five- or six-membered heterocyclic group, and n and m each represent integers of 2 to 5, or salts thereof. These compounds possess cholinolytic and bronchospasmolytic effects and are completely devoid of harmful side-effects. Thus these compounds can be used to great advantage in therapy. The new compounds of the formula (I) or their salts can be prepared by reacting a diaminoalcohol of the formula (III), ##STR3## wherein R.sub.2 is lower alkyl or a group of formula -(CH.sub.2).sub.m -OH, with a reactive derivative of xanthene-9-carboxylic acid, and, if desired, converting the obtained product into its salt.
本发明涉及公式(I)的新型黄色素-9-羧酸酯,其中R1和R3相同或不同,均可代表较低的烷基,R2是较低的烷基或公式(VI)的基团,其中M是2至5的整数,或R1和R2与相邻的氮原子一起形成五元或六元杂环基团,n和m各代表2至5的整数,或其盐。这些化合物具有胆碱能和支气管痉挛能效应,并且完全没有有害副作用。因此,这些化合物在治疗中具有极大的优势。公式(I)的新化合物或其盐可通过将公式(III)的二氨基醇与黄色素-9-羧酸的反应衍生物反应,并根据需要将所得产物转化为其盐来制备。